OPRX OptimizeRx Corporation

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

  

Date of Report (Date of Earliest Event Reported): October 20, 2023

 

OptimizeRx Corporation

(Exact name of registrant as specified in charter)

 

Nevada		001-38543		26-1265381
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

260 Charles Street, Suite 302, Waltham, MA		02453
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: 248.651.6568

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 Par Value		OPRX		The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Introductory Note

 

As previously disclosed, on October 11, 2023, OptimizeRx Corporation (the “Company” or “OptimizeRx”) entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with Healthy Offers, Inc. (d/b/a Medicx Health), a Nevada corporation (“Medicx”), the securityholders of Medicx named therein (the “Securityholders”), and Michael Weintraub, not in his individual capacity, but solely in his capacity as representative, agent and attorney-in-fact of the Securityholders.

 

On October 24, 2023, pursuant to the Merger Agreement, a newly formed wholly-owned subsidiary of the Company consummated the merger with and into Medicx, with Medicx continuing as the surviving company and a wholly-owned subsidiary of the Company (the “Merger”). The aggregate merger consideration the Company paid to the Securityholders of Medicx at the closing was $95,000,000, subject to certain customary post-acquisition purchase price adjustments.

 

Item 1.01 Entry into a Material Definitive Agreement.

 

As previously disclosed, certain members of Medicx’s management team (“Management Investors”) agreed to use a portion of the consideration received pursuant to the Merger Agreement to purchase, in the aggregate, approximately $10.5 million of the Company’s common stock. On October 24, 2023, at the closing of the Merger, each Management Investor executed a common stock purchase agreement (the “Subscription Agreement”) to memorialize his or her purchase.

 

Pursuant to the Subscription Agreement, the Company issued 1,444,581 shares of its common stock in the aggregate to the Management Investors. Each Management Investor received the number of shares of the Company’s common stock equal to: (i) the aggregate amount to be invested by such Management Investor, divided by (ii) $7.223, the volume-weighted average of the trading prices on the Nasdaq Capital Market for one share of the Company’s common stock for the five consecutive trading days ending the trading day immediately preceding the date that the Merger Agreement was executed, which shares of common stock were rounded up to the nearest whole number of shares of common stock (on an aggregate basis per Management Investor), in lieu of receiving any amount of cash or fractional shares of common stock. The shares of OptimizeRx common stock issued to the Management Investors have not been registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.

 

The foregoing description of the Subscription Agreement and the transactions contemplated by the Subscription Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Subscription Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

 

Item 2.01. Completion of Acquisition or Disposition of Assets.

 

The Merger was completed on October 24, 2023. The description of the Merger included under the Introductory Note of this Current Report on Form 8-K is incorporated into this Item 2.01 by reference.

 

The financial statements of Medicx and the pro forma financial information of OptimizeRx required under Item 9.01 of this report will be filed by amendment not later than 71 calendar days after the date on which this Current Report on Form 8-K related to the closing of the Merger is required to be filed.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The disclosure set forth above under Item 1.01 of this Current Report is incorporated by reference into this Item 3.02.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

 

As previously disclosed, the Board determined to appoint Stephen L. Silvestro President of the Company effective as of the closing of the Merger. In connection therewith, on October 20, 2023, the Compensation Committee determined to increase Mr. Silvestro’s base salary, effective as of the closing of the Merger, to $400,000 per annum.

  

Item 7.01 Regulation FD Disclosure.

   

On October 25, 2023, the Company issued a press release announcing the closing of the Merger. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

 

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto are furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibit

 

(a)

Financial Statements of Businesses Acquired

 

The audited financial statements and unaudited interim financial statements of Medicx required by this Item 9.01(a) will be filed by amendment not later than 71 calendar days after the date on which this Current Report on Form 8-K related to the closing of the Merger is required to be filed.

 

(b)

Pro Forma Financial Information

 

The unaudited pro forma financial information required by this Item 9.01(b) will be filed by amendment not later than 71 calendar days after the date on which this Current Report on Form 8-K related to the closing of the Merger is required to be filed.

 

(d) Exhibits

 

Exhibit Number		Description
10.1*		Common Stock Purchase Agreement dated October 24, 2023 by and among the Company and the Management Investors
99.1		Press Release of OptimizeRx dated October 25, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

  

*	Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit to the SEC upon request.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

	OPTIMIZERX CORPORATION
Date: October 25, 2023	By:	/s/ Edward Stelmakh
		Name: Edward Stelmakh
		Title: Chief Financial Officer

 

 

3

Exhibit 10.1

 

CONFIDENTIAL

 

COMMON STOCK PURCHASE AGREEMENT

 

This Common Stock Purchase Agreement (this “Agreement”) is made and entered into as of this ___ day of ____________, 2023, by and among OptimizeRx Corporation, a Nevada corporation (the “Company”), and the individuals listed on Exhibit A hereto (the “Purchasers”).

 

Background

 

A. The Company is a party to that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of October 11, 2023, by and among the Company and the other parties named therein;

 

B. Pursuant to the Merger Agreement, each of the Purchasers is entitled to receive certain consideration as payment for securities; and

 

C. Each of the Purchasers has, in connection with the Merger Agreement, agreed to use a portion of the consideration received pursuant to the Merger Agreement to purchase shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), as further set forth herein.

 

In consideration of the mutual promises and covenants contained in this Agreement, the parties hereto agree as follows:

 

1. Sale of Shares. Subject to the terms and conditions of this Agreement, at the Closing the Company will sell and issue to each of the Purchasers, and each of the Purchasers will purchase, the number of shares of Common Stock set forth opposite such Purchaser’s name on Exhibit A for the purchase price per share equal to $7.223. The shares of Common Stock being sold under this Agreement are collectively referred to as the “Shares.” The Company’s agreement with each of the Purchasers is a separate agreement, and the sale of Shares to each of the Purchasers is a separate sale.

 

2. The Closing. The closing (“Closing”) of the sale and purchase of the Shares under this Agreement shall take place concurrently with the execution of this Agreement. At the Closing, the Company will deliver to each of the Purchasers the number of Shares being purchased by such Purchaser solely in book entry form, registered in the name of such Purchaser, against payment to the Company of the purchase price therefor. For the avoidance of doubt, the parties hereto acknowledge and agree that, in the interest of efficiency, rather than paying to each Purchaser the full amount of the consideration to which such Purchaser was entitled under the Merger Agreement, the Company retained a portion of such consideration in an amount equal to such Purchaser’s aggregate purchase price for the Shares and that, by permitting the Company to retain such amount (and the Company so retaining such amount), such Purchaser’s obligation to pay the purchase price for the Shares has been fully satisfied.

 

3. Representations of the Company. The Company hereby represents and warrants to each of the Purchasers as follows:

 

3.1 Organization. The Company is a corporation duly organized, existing, and in good standing under the laws of the State of Nevada and it has the corporate power and authority to own or lease its properties and to conduct its business as it is now being conducted and to enter into and perform this Agreement and to carry out the transactions contemplated by this Agreement. The Company is duly qualified and is in good standing (or equivalent status) in each jurisdiction in which the property leased or operated by such party or the nature of the business conducted by such party makes such qualification necessary.

 

 

3.2 Capitalization. The authorized capital stock of the Company consists of 166,666,667 shares of Common Stock and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share.

 

3.3 Issuance of Shares. The issuance, sale, and delivery of the Shares in accordance with this Agreement, have been duly authorized by all necessary corporate action on the part of the Company. The Shares when so issued, sold and delivered against payment therefor in accordance with the provisions of this Agreement will be duly and validly issued, fully paid, and nonassessable.

 

3.4 Authority for Agreement. The execution, delivery, and performance by the Company of this Agreement, and the consummation by the Company of the transactions contemplated hereby, have been duly authorized by all necessary corporate action. This Agreement has been duly executed and delivered by the Company and constitutes the valid and binding obligation of the Company enforceable in accordance with its terms.

 

3.5 Noncontravention. Neither the execution and the delivery of this Agreement nor the consummation of the transactions contemplated by this Agreement, will (a) violate any provision of its organizational documents or (b) constitute a default under, or result in a breach or violation of any of the terms and provisions of, any contract or agreement of the Company, except in the case of (b) as would not, individually or in the aggregate, be reasonably expected to materially adversely affect the condition (financial or otherwise), prospects, earnings, business or properties of the Company.

 

3.6 SEC Filings. The Company has timely filed with or furnished to, as applicable, the Securities and Exchange Commission (the “SEC”) all reports, schedules, forms, statements, and other documents (including exhibits and all other information incorporated by reference) required to be filed or furnished by it with the SEC since January 1, 2020 (the “Company SEC Documents”). True, correct, and complete copies of all the Company SEC Documents are publicly available on the Electronic Data Gathering, Analysis, and Retrieval database of the SEC. As of their respective filing dates or, if amended or superseded by a subsequent filing prior to the date hereof, as of the date of the last such amendment or superseding filing (and, in the case of registration statements and proxy statements, on the dates of effectiveness and the dates of the relevant meetings, respectively), each of the Company SEC Documents complied as to form in all material respects with the applicable requirements of the Securities Act of 1933, the Securities Exchange Act of 1934, and the rules and regulations of the SEC thereunder applicable to such Company SEC Documents. None of the Company SEC Documents, including any financial statements, schedules, or exhibits included or incorporated by reference therein at the time they were filed (or, if amended or superseded by a subsequent filing prior to the date hereof, as of the date of the last such amendment or superseding filing), contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. To the knowledge of the Company, none of the Company SEC Documents is the subject of ongoing SEC review or outstanding SEC investigation and there are no outstanding or unresolved comments received from the SEC with respect to any of the Company SEC Documents.

 

 

4. Representations of the Purchasers. Each of the Purchasers severally represent and warrant to the Company as follows:

 

4.1 Investment. Such Purchaser is acquiring the Shares for such Purchaser’s own account for investment and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling the same; and such Purchaser has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness, or commitment providing for the disposition thereof. Such Purchaser understands that the Shares are “restricted securities” and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any applicable state securities law. Such Purchaser is not purchasing the Shares as a result of any advertisement, article, notice or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.

 

4.2 Authority. Such Purchaser has full power and authority to enter into and to perform this Agreement in accordance with its terms.

 

4.3 Experience. Such Purchaser has carefully reviewed the representations concerning the Company contained in this Agreement, and has made detailed inquiry concerning the Company, its business, and its personnel; the officers of the Company have made available to such Purchaser any and all written information that such Purchaser has requested and have answered, to such Purchaser’s satisfaction, all inquiries made by such Purchaser; and such Purchaser has adequate net worth and means of providing for such Purchaser’s current needs and personal contingencies to sustain a complete loss of such Purchaser’s investment in the Company; such Purchaser’s overall commitment to investments that are not readily marketable is not disproportionate to such Purchaser’s net worth and such Purchaser’s investment in the Shares will not cause such overall commitment to become excessive.

 

4.4 Accredited Investor. Such Purchaser represents that he, she or it is an accredited investor within the meaning of Regulation D under the Securities Act. Such Purchaser acknowledges that he, she or it has completed the Investor Questionnaire, in substantially the form attached hereto as Exhibit B, and that the information contained therein is complete and accurate as of the date thereof and is hereby affirmed as of the date hereof. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification Event”) is applicable to (i) such Purchaser or (ii) any of such Purchaser’s Rule 506(d) Related Parties (as defined below). Such Purchaser hereby agrees that such Purchaser shall notify the Company promptly in writing in the event a Disqualification Event becomes applicable to such Purchaser or any of such Purchaser’s Rule 506(d) Related Parties. “Rule 506(d) Related Party” shall mean (a) a person or entity that controls such Purchaser, or (b) a person or entity that, directly or indirectly, has or shares, or is deemed to have or share, voting or dispositive power with respect to securities owned by such Purchaser.

 

 

4.5 Residency. Such Purchaser is a resident of the state set forth on Exhibit A hereto and is not acquiring the shares of the Company’s Common Stock as a nominee or agent or otherwise for any other person.

 

4.6 Acknowledgment. Such Purchaser understands the meaning and legal consequences of the representations and warranties in this Section 4 and acknowledges and agrees that the Company is relying upon such representations and warranties in determining to issue the shares of the Company’s Common Stock to such Purchaser and in establishing that such issuance and sale is exempt from the registration requirements of the Securities Act.

 

4.7 Restrictions on Transfer. Such Purchaser understands that the shares of Common Stock being issued hereunder are “restricted securities” under applicable federal securities laws and that the Securities Act and the rules of the U.S. Securities and Exchange Commission provide in substance that such Purchaser may dispose of such share of Common Stock only pursuant to an effective registration statement under the Securities Act or an exemption therefrom, and such Purchaser understands that the Company has no obligation or intention to register any of the Shares, or to take action so as to permit sales pursuant to the Securities Act. Such Purchaser understands that the Company is not required to register the Shares or to make any exemption from registration available.

 

5. Indemnification. To the fullest extent permitted by Delaware law, as the same now exists or may hereafter be amended, substituted, or replaced, the Company shall indemnify, hold harmless, defend, pay, and reimburse each of the Purchasers from and against any and all losses, claims, damages, judgments, fines, or liabilities, including reasonable legal fees or other expenses incurred in investigating or defending against such losses, claims, damages, judgments, fines, or liabilities, and any amounts expended in settlement of any claims to which each of the Purchasers may become subject by reason of any failure of the Company to perform any covenant or agreement made or contained herein or fulfill any obligation in respect thereof.

 

6. Confidentiality. Each Purchaser agrees that he, she or it will keep confidential and will not disclose or divulge any confidential, proprietary, or secret information that such Purchaser may obtain from the Company pursuant to financial statements, reports, and other materials submitted by the Company to such Purchaser pursuant to this Agreement, or pursuant to visitation or inspection rights granted hereunder (“Confidential Information”), unless such information is known, or until such information becomes (through no improper action or inaction by Purchaser or anyone to whom Purchaser disclosed Confidential Information) known, to the public; provided, however, that a Purchaser may disclose such information (i) to such Purchaser’s attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with such Purchaser’s investment in the Company provided that such attorneys, accountants, consultants, and other professionals are bound by obligations of confidentiality and non-use that are as stringent as those contained in this Agreement, (ii) to any prospective purchaser of any Shares from such Purchaser as long as such prospective purchaser agrees in writing to be bound by the provisions of this Section 6, or (iii) to any affiliate of such Purchaser or to a partner, shareholder or subsidiary of such Purchaser. Purchaser agrees to use the Confidential Information for the sole purpose of considering Purchaser’s investment in the Company and not to engage in any trading of the Company’s common stock based the Confidential Information, unless such information is known, or until such information becomes (through no improper action or inaction by Purchaser or anyone to whom Purchaser disclosed Confidential Information) known, to the public.

 

 

7. Notices. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall be delivered by hand or mailed by first class certified or registered mail, return receipt requested, postage prepaid:

 

7.1 If to the Company, at 260 Charles Street, Suite 302, Waltham, MA 02453, Attention: Corporate Secretary, or at such other address or addresses as may have been furnished in writing by the Company to the Purchasers, with a copy to General Counsel, Marion Odence-Ford.

 

7.2 If to a Purchaser, at such Purchaser’s address set forth on Exhibit A, or at such other address or addresses as may have been furnished to the Company in writing by such Purchaser.

 

8. Expenses. Except as otherwise expressly provided herein, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses.

 

9. Entire Agreement. This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter.

 

10. Amendments and Waivers. Except as otherwise expressly set forth in this Agreement, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the holders of at least 50% of the Shares. Any amendment or waiver effected in accordance with this Section 10 shall be binding upon each holder of any Shares, each future holder of all such securities, and the Company. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision.

 

11. Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

12. Headings. The headings of the sections, subsections, and paragraphs of this Agreement have been added for convenience only and shall not be deemed to be a part of this Agreement.

 

13. Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision.

 

14. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, excluding that body of laws pertaining to conflicts of laws. Courts within the state of Delaware will have exclusive jurisdiction over all disputes between the parties hereto arising out of or relating to this Agreement. The Company and the Purchasers each knowingly and willingly consent to and agree to submit to the exclusive jurisdiction of such courts, to the exclusion of any other courts.

 

[Signature Page Follows]

 

 

IN WITNESS WHEREOF, the undersigned have hereunto set their hands as of the day and year first above written.

 

	COMPANY:
	OptimizeRx Corporation
	By:	/s/ William J. Febbo
		Name:	William J. Febbo
		Title:	Chief Executive Officer
	PURCHASERS:
	/s/ Michael Weintraub
	Michael Weintraub
	/s/ Frank Hicks
	Frank Hicks
	/s/ Theresa Greco
	Theresa Greco
	/s/ Chad Gottfrid
	Chad Gottfrid
	/s/ Karin Chun Hayes
	Karin Chun Hayes
	/s/ Stacey Levas
	Stacey Levas

 

 

 

Exhibit 99.1

 

 

 

OptimizeRx Announces Completion of Medicx
Acquisition and Sets Third Quarter 2023 Conference
Call for November 6, 2023, at 8:30 a.m. ET

 

Executive Leadership expands with Steve Silvestro being promoted to President, and Theresa Greco assuming the role of Chief Commercial Officer

  

WALTHAM, Ma. – October 25, 2023 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has successfully completed its acquisition of Healthy Offers, Inc., dba Medicx Health ("Medicx”), a leading healthcare consumer-focused omnichannel marketing and analytics company. The two companies will operate independently through 2023 with full integration during the first quarter of 2024. The Company will hold a conference call on Monday, November 6, 2023, at 8:30 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2023, as well as details of the acquisition. OptimizeRx third quarter financial results will be issued in a press release prior to the call.

 

With the closing of the Medicx acquisition, the Company will expand its executive team with the addition of Medicx’s President, Theresa Greco, becoming the Chief Commercial Officer of OptimizeRx. Theresa will lead commercial strategy and execution for the Company and report directly to Steve Silvestro. Theresa is an experienced commercial leader having driven growth as an executive of multiple large-scale healthcare-focused organizations prior to taking the helm at Medicx, including at Prognos Health, MMIS, Lexis Nexis, and CSC.

 

“Theresa brings a wealth of knowledge and demonstrated results directing commercial and business strategies for organizations focused on data and technology solutions for life sciences,” said Will Febbo chief executive officer, OptimizeRx. “I’m confident that her balanced approach, knowledge of our customers, and commitment to growth will position us to bring our organizations together as a commercial powerhouse focused on meeting the strategic engagement needs of our customers and expanding our footprint within our combined books of business.”

 

Steve Silvestro will step into a new role as President, leading all aspects of corporate strategy and daily business management.

 

 

“Steve’s commercial leadership has resulted in our business more than doubling in size during his tenure here. He was also instrumental in the development of our Dynamic Audience Activation Platform (DAAP), which is a key internal technological advancement that made the acquisition of Medicx possible,” continued Febbo, “I’m pleased to announce Steve’s new role of President, which will be a very natural transition for both Steve and the Company. Steve’s leadership style has always extended organizationally, and in my eyes, this is a testament to his commitment to strategically positioning us with our customers and partners, which has been transformative to our go-to-market over the past four years.”

 

No other leadership changes will occur at the executive level.

 

Conference Call Details

 

OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

 

Date:	Monday, November 6, 2023
Time:	8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)
Toll Free:	1-877-423-9813
International:	1-201-689-8573
Conference ID:	13742267
Call Me Link:	https://callme.viavid.com/viavid/?callme=true&passcode=13742267&h=true&info=company-email&r=true&B=6
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1640427&tp_key=4d243008bb

 

Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

 

A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at www.optimizerx.com/investors.  

 

About OptimizeRx

 

OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as web display and social media, OptimizeRx helps life sciences organizations engage and support their customers.

 

For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com.

  

 

About Medicx Health

 

Medicx Health leverages real world evidence with innovative SaaS analytics to drive clinical and commercial strategy and execution with measurable ROI for hundreds of life sciences brands. The company’s patented Micro-Neighborhood® Targeting technology fuels the industry’s highest quality performance for consumer and healthcare provider audiences. Medicx uniquely supports brand and agency clients to plan optimized audience targets, execute efficient omni-channel engagement, as well as measure performance across all channels in a single closed-loop and privacy-compliant environment. Visit medicxhealth.com to learn more.

 

Important Cautions Regarding Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

 

OptimizeRx Contact 

 

Andy D’Silva, SVP Corporate Finance

adsilva@optimizerx.com

 

Investor Relations Contact

 

Ashley Robinson

LifeSci Advisors, LLC

arr@lifesciadvisors.com

 

 

3

v3.23.3

Cover	Oct. 20, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 20, 2023
Entity File Number	001-38543
Entity Registrant Name	OptimizeRx Corporation
Entity Central Index Key	0001448431
Entity Tax Identification Number	26-1265381
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	260 Charles Street
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	248
Local Phone Number	651.6568
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 Par Value
Trading Symbol	OPRX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

---